NCT03878095: Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

NCT03878095
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: IDH
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have biopsy-confirmed evidence of an IDH1 or IDH2 mutation; Patients with stable & active brain metastases or leptomeningeal disease are eligible – see trial for specific requirements
Exclusions: Patients with previous treatment with AZD6738 or any other ATR inhibitor
https://ClinicalTrials.gov/show/NCT03878095

Comments are closed.

Up ↑